# GHK-Cu: Wound Healing, Collagen, and Tissue Remodeling Research > GHK-Cu is a naturally occurring copper tripeptide with a 50-year research record in wound healing, collagen synthesis, and tissue remodeling. Summaries of the published literature. GHK-Cu is a three-amino-acid copper complex found naturally in human plasma. It has been studied for wound contraction, collagen synthesis, hair follicle stimulation, and gene expression modulation across in vitro models, rodent studies, and small human trials. ## What Is GHK-Cu? GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a tripeptide — three amino acids: glycine, histidine, and lysine — that binds copper(II) ions. It is found naturally in human plasma, saliva, and urine, and it has a molecular weight of just 340.4 Da. Plasma levels are meaningful: approximately 200 ng/mL (10⁻⁷ M) at age 20, falling to roughly 80 ng/mL by age 60 [3]. That age-related decline correlates with reduced collagen synthesis rates, slower wound closure, and declining skin integrity in the published literature [3]. GHK-Cu is not a synthetic drug. The amino acid sequence glycine-histidine-lysine is present in the alpha-2(I) chain of type I collagen — when collagen is proteolytically degraded at a wound site, GHK is released locally and binds available copper ions, acting as a signaling molecule to coordinate the tissue repair response [1]. The compound has been studied since the 1970s. The research literature spans collagen and extracellular matrix synthesis, wound healing, hair follicle biology, anti-inflammatory and antioxidant pathways, pulmonary protection, and gene expression modulation in aging cells. ## What Does GHK-Cu Peptide Do? GHK-Cu stimulates collagen biosynthesis in human fibroblast cultures at concentrations between 10⁻¹² and 10⁻⁹ M, with peak activity at 10⁻⁹ M, independent of any change in cell number [1]. That is a finding from 1988 that has been replicated and built upon across multiple subsequent studies. Beyond collagen, GHK-Cu modulates the expression of approximately 31.2% of human genes at a ≥50% change threshold — upregulating 59% and suppressing 41% of affected genes [2]. The activated sets include 47 DNA repair genes, 41 ubiquitin-proteasome genes, and 408 neuronal function genes [2]. The most studied effects: - **Wound healing and tissue contraction.** GHK-Cu in a collagen wound dressing increased local collagen 9-fold and reduced TNF-α in diabetic and ischemic rat wounds [7]. A liposomal GHK-Cu formulation closed scald wounds in mice within 14 days while enhancing VEGF, FGF-2, and CDK4 expression vs. free GHK-Cu controls [8]. - **Collagen and skin remodeling.** A 12-week placebo-controlled trial in 71 women showed improved skin density, reduced laxity, and measurable wrinkle reduction [4]. A nano-lipid carrier formulation produced a 31.6% reduction in wrinkle volume in an 8-week double-blind trial [6]. - **Hair follicle stimulation.** A randomized double-blind 6-month trial in 45 male pattern hair loss patients using a GHK complex showed a hair count increase of 52.6 vs. 9.6 in placebo (p<0.05) [12]. - **Anti-inflammatory and antioxidant activity.** GHK-Cu completely blocked copper-dependent LDL oxidation and reduced ferritin iron release by 87% in biochemical assays — outperforming superoxide dismutase [9]. These are measured effects in defined models. Human pharmacokinetic data for injectable GHK-Cu are absent from the published literature, and no FDA-approved therapeutic indication exists for systemic use. ## GHK Copper Peptide: The Science of a Naturally Occurring Tripeptide The term "GHK copper peptide" refers to the same molecule as GHK-Cu: the glycine-histidine-lysine tripeptide in its copper(II)-bound form. Both spellings map to the same compound and the same literature. The copper-bound form is mechanistically distinct from GHK alone. In fibroblast culture experiments, stimulation of MMP-2 (matrix metalloproteinase-2) required the copper-bound complex — copper ions alone reproduced the effect, but the GHK tripeptide without copper did not [19]. This means the copper binding is not incidental: it is what enables the extracellular matrix remodeling pathway. Key signaling pathways activated by GHK-Cu include: - **NF-κB suppression** — reducing pro-inflammatory cytokine expression - **Nrf2/Keap1 upregulation** — activating antioxidant response genes (HO-1, glutathione) - **VEGF and FGF-2 upregulation** — promoting angiogenesis at wound sites - **Wnt/β-catenin activation** — driving hair follicle cycling - **TGF-β1/Smad pathway modulation** — balancing tissue repair against excess fibrosis - **Integrin-β1 pathway activation** — enabling fibroblast migration and collagen gel contraction [2, 10, 11, 21] The [GHK-Cu mechanism of action](/research#mechanism) is broad: it is less a single-target drug than a pleiotropic signaling peptide that orchestrates tissue repair responses across multiple pathways simultaneously. For detailed wound healing and collagen synthesis findings, see the [GHK-Cu wound healing studies](/research#wound-healing) and [copper peptide benefits](/benefits) pages. ## The Research Evidence: What Is Established and What Is Not GHK-Cu has the strongest evidence base in three areas: 1. **Topical wound healing and skin remodeling.** Multiple controlled trials and a substantial in vitro literature. Human randomized controlled trial data exists for topical formulations — this is the most clinically supported domain [4, 6, 24]. 2. **Hair follicle stimulation.** One 6-month double-blind RCT in male pattern hair loss patients shows statistically significant hair count increases [12]; a 2023 mouse model study shows faster anagen induction than topical minoxidil [13]. 3. **Gene expression modulation.** Pickart's microarray analyses show broad effects on tissue repair, anti-inflammatory, DNA repair, and neuronal gene sets [2]. These findings are mechanistically compelling but functionally unvalidated across all gene targets. Where the evidence thins: - **Injectable GHK-Cu in humans.** No published pharmacokinetic studies, no human RCTs. Injectable use in functional medicine and research contexts is not supported by clinical trial data. - **Neuroprotection in humans.** Two 2023 preprint studies in aging and Alzheimer's mouse models show promising intranasal GHK-Cu results [14, 15]; human translation is not yet demonstrated. - **Long-term systemic safety.** No chronic human safety data. Rodent studies have not demonstrated toxicity at studied doses, but copper homeostasis concerns at high or prolonged doses are noted in the preclinical literature. This site documents the published record as it stands. For [frequently asked questions about GHK-Cu](/faq), including safety and comparison questions, see the FAQ. --- Wound healing, collagen, and tissue remodeling: plain-language summaries of the GHK-Cu research record, cited study by study, written by no clinic and sold by no one.